Flash Delivery Platform
Technology Platform Overview
FLASH Delivery System: Broad-Spectrum, High-Efficiency, Low-Toxicity
One of the core bottlenecks in gene editing is delivery—how to efficiently and safely introduce editing tools into target cells, especially "hard-to-transfect" types like stem cells, primary cells, and immune cells.
The FLASH delivery system is EDITGENE's proprietary broad-spectrum gene editing delivery platform. Based on an optimized protein/nucleic acid co-delivery vector, the FLASH system facilitates simultaneous delivery of the RNP complex and Donor DNA. It dramatically elevates editing efficiency while maintaining exceptionally low cytotoxicity.
To date, the FLASH system has been validated in over 400 cell lines and is widely applied across three core scenarios: Gene Knockout (Flash-KO), Point Mutation (Flash-PE7), and Gene Knock-in (Flash-KI).
Core Technical Advantages
Broad Applicability:
Successfully deployed in 400+ cell lines, demonstrating exceptional performance in notoriously difficult cells like iPSCs, hESCs, organoids, and immune cells.
Ultra-High Editing Efficiency:
Knockout efficiency exceeds 80% in 53% of tested cell lines; point mutation pool efficiency reaches up to 98%; knock-in efficiency reaches 88%, outperforming conventional methods across the board.
Knockout efficiency exceeds 80% in 53% of tested cell lines; point mutation pool efficiency reaches up to 98%; knock-in efficiency reaches 88%, outperforming conventional methods across the board.
Minimal Cytotoxicity:
An innovative protein delivery strategy entirely circumvents the immunogenicity and random integration risks associated with DNA plasmids, consistently keeping cell viability above 90%.
An innovative protein delivery strategy entirely circumvents the immunogenicity and random integration risks associated with DNA plasmids, consistently keeping cell viability above 90%.
Versatile Applications:
Comprehensively covers Gene Knockout (Flash-KO), Precision Point Mutation (Flash-PE7), and Gene Knock-in (Flash-KI).
Comprehensively covers Gene Knockout (Flash-KO), Precision Point Mutation (Flash-PE7), and Gene Knock-in (Flash-KI).
FLASH vs. Conventional Delivery Methods
| Metric | Viral Vectors (Lentivirus/AAV) | Electroporation | Lipofection | FLASH Delivery System |
| Applicability | Limited (low efficiency in iPSCs/T cells; AAV capacity limits) | Broad, but highly damaging; low in neurons | Okay for standard cells; poor for stem/suspension cells | Validated in 400+ lines (incl. iPSCs, hESCs, organoids, immune cells) |
| Cycle Time | 2-3 weeks for LV; longer for AAV | Hours | Hours | Hours (Ready-to-use RNP, no packaging) |
| Efficiency | Low KI (HDR <10%); prone to silencing | KO 30-70%; KI <20% | KO 30-70%; KI <10% | KO: >80% in 53% of lines; PE: 98% pool; KI: 5-7x increase |
| Cytotoxicity | Low to moderate (mutation risk via integration) | High (30-50% cell death) | Moderate | Low (>90% viability post-transfection) |
| Division Dependency | LV requires division; AAV does not | KI requires HDR (division) | KI requires HDR | PE7 works in non-dividing cells; KI + NHEJ inhibitor boosts efficiency in non-dividing cells |
| Selection Need | Antibiotic selection often required (1-2 weeks) | Often required | Often required | Selection-free high-purity pools achievable (e.g., 293T KI 88%) |
| Integration Risk | High (viral integration into host genome) | None (transient) | None (transient) | None (transient protein/RNA expression) |
| Applicability | Limited (low efficiency in iPSCs/T cells; AAV capacity limits) | Broad, but highly damaging; low in neurons | Okay for standard cells; poor for stem/suspension cells | Validated in 400+ lines (incl. iPSCs, hESCs, organoids, immune cells) |
Service Types
Standard Services
| Service Type | Technical Solution | Target Scenarios | Deliverables | Turnaround |
| Gene Knockout | FLASH-RNP + UP.SIGHT Single-cell Screening | KO in standard and hard-to-transfect cells | Homozygous monoclonal lines (≥2) + Sequencing report | 8-12 weeks |
| Point Mutation | FLASH-PE7 Prime Editing | Single base substitution, small indels (applicable to non-dividing cells) | Homozygous PM monoclonal line + Sequencing report | 10-14 weeks |
| Gene Knock-in | FLASH-KI + NHEJ Inhibitor | Reporter KI, tag insertion, conditional KI | Homozygous KI monoclonal line + Sequencing report | 10-14 weeks |
| Single-Cell | UP.SIGHT + CFM Supplement + In situ | One-step KO/PM | Single-cell derived | 8-10 weeks |
| Editing | FLASH-RNP | monoclonal generation | homozygous monoclonal line + QC report |
Custom Services
| Customization Type | Description | Turnaround Time | Remarks |
| Large Fragment Knock-in | Targeted integration of >4kb fragments (e.g., full-length genes, regulatory elements) | 13-16 Weeks | Requires assessment of Donor design and cell tolerance |
| High-Throughput Editing | Parallel editing in 96-well plates (≥48 targets) | 10-12 Weeks | Ideal for CRISPR library screening |
| Hard-to-Transfect Specialties | Specific cell types including primary cells, neurons, and organoids | 12-16 Weeks | Pilot experiments required for parameter optimization |
Standardized Marketing Data (Service Capability Summary)
| Metric | Data |
| Validated Cell Lines | 400+ |
| Gene Knockout (KO) Success Rate | >95% (Standard lines); >80% (Hard-to-transfect) |
| Point Mutation Success Rate | 83% (Overall) |
| Knock-in (KI) Success Rate | 70-90% (Depending on complexity) |
| Fastest Delivery Cycle | 8 Weeks (Single-cell editing / Standard KO) |
| Cumulative Delivered Cases | 3000+ (Combined total for KO, Point Mutation, and KI) |
Application Cases
-
Case 1: High-Efficiency Knockout Data across Diverse Cell Lines
- To validate the broad applicability and high efficiency of the FLASH-RNP system, we conducted gene knockout tests on nearly 100 cell lines from various tissue origins and species. This study encompassed tumor cells, standard immortalized cell lines, stem cells, immune cells, and organoids.
The results demonstrate:
•53% of the cell lines achieved knockout efficiencies exceeding 80%.
•88% of the cell lines achieved knockout efficiencies exceeding 30%.
•Even in traditionally hard-to-transfect cells—such as iPSCs, hESCs, primary T cells, and organoids—the knockout efficiency was significantly superior to conventional methods.
Case 2: iPSC Dual-Allele Knockout (CIITA, B2M)
Solution: FLASH-RNP co-delivery of two sgRNAs.
Result: 64% and 75% efficiency respectively; homozygous double-KO clones isolated in 3 weeks with pluripotency intact.
Representative real-world case studies (design logic + experimental workflow + delivery process + after-sales support)
Case 3: hESC TH Gene C-Terminal EGFP Knock-in
Solution: FLASH-KI + NHEJ Inhibitor.
Result: 20% KI efficiency; obtained stable reporter line with normal karyotype and preserved pluripotency.
